A Prospective, Multi-cohort Clinical Research of Efficacy and Safety of Bispecific Anti-PD-1 / PD-L1 Antibody IBI318 Combined With Lenvatinib in the Treatment of Advanced NSCLC

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

20 Dec 2023 Planned number of patients changed from 100 to 120.
20 Dec 2023 Planned End Date changed from 1 Nov 2023 to 25 Dec 2025.
20 Dec 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com